CKD-385: An Investigative Report on its Profile, Clinical Development, and Current Status

1. Executive Summary

CKD-385 is identified as a small molecule drug developed by Chong Kun Dang Pharmaceutical Corp..[1] Its primary therapeutic focus has been cardiovascular diseases, with investigations into angina pectoris, heart failure, and hypertension.[1] The clinical development program for CKD-385 involved a series of Phase 1 trials initiated in South Korea around 2020-2021. These studies were designed to evaluate the pharmacokinetic (PK) properties and safety of CKD-385, including high-dose formulations, in healthy volunteers under both fed and fasting conditions.[1] Older information also suggests a potential, likely discontinued, Phase 2 study for hypertension in the United States.[1]

Despite this early-phase clinical activity, a significant uncertainty surrounds CKD-385's current development trajectory. The compound is notably absent from Chong Kun Dang Pharmaceutical Corp.'s recent official R&D pipeline disclosures.[4] This omission, coupled with reports from pharmaceutical databases indicating an "Unknown status" for its clinical trials or "No recent reports of development" as of early 2024 [1], strongly suggests that the development of CKD-385 may have been deprioritized, paused, or discontinued. Furthermore, critical details such as its specific molecular target, a comprehensive mechanism of action, definitive chemical structure (including CAS Number), and any published results from its clinical trials are largely unavailable in the public domain based on the provided information.

2. CKD-385: Profile and Developer

2.1. Chemical Nature and Identification